Annexon, Inc. (ANNX)
Largest Insider Buys in Sector
ANNX Stock Price History Chart
ANNX Stock Performance
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with …
Insider Activity of Annexon, Inc.
Over the last 12 months, insiders at Annexon, Inc. have bought $1.15M and sold $381,570 worth of Annexon, Inc. stock.
On average, over the past 5 years, insiders at Annexon, Inc. have bought $14.78M and sold $1.09M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Satter Muneer A () — $6.05M. Carson William H. (director) — $139,517.
The last purchase of 3,200 shares for transaction amount of $17,056 was made by Carson William H. (director) on 2024‑12‑02.
List of Insider Buy and Sell Transactions, Annexon, Inc.
| 2024-12-02 | director | 3,200 0.003% | $5.33 | $17,056 | -5.60% | |||
| 2024-10-15 | Sale | EVP & CHIEF INNOVATION OFFICER | 5,408 0.0062% | $7.41 | $40,073 | -28.66% | ||
| 2024-10-01 | director | 3,200 0.003% | $5.97 | $19,104 | +2.29% | |||
| 2024-09-19 | Sale | EVP & CHIEF INNOVATION OFFICER | 4,500 0.0043% | $7.10 | $31,950 | -11.66% | ||
| 2024-09-12 | Sale | EVP & CHIEF INNOVATION OFFICER | 5,500 0.0048% | $6.16 | $33,880 | -3.64% | ||
| 2024-09-05 | Sale | EVP & CHIEF INNOVATION OFFICER | 5,500 0.005% | $5.64 | $31,020 | +9.19% | ||
| 2024-09-03 | director | 3,200 0.0031% | $5.48 | $17,536 | +15.90% | |||
| 2024-08-29 | Sale | EVP & CHIEF INNOVATION OFFICER | 5,500 0.0052% | $5.95 | $32,725 | +5.14% | ||
| 2024-08-01 | director | 3,200 0.0031% | $6.24 | $19,968 | -1.31% | |||
| 2024-07-15 | Sale | EVP & CHIEF BUSINESS OFFICER | 784 0.0011% | $6.02 | $4,720 | 0.00% | ||
| 2024-07-15 | Sale | EVP & CHIEF FINANCIAL OFFICER | 1,104 0.0016% | $6.03 | $6,657 | 0.00% | ||
| 2024-07-15 | Sale | EVP & CHIEF INNOVATION OFFICER | 1,106 0.0016% | $6.02 | $6,658 | 0.00% | ||
| 2024-07-01 | director | 3,200 0.0038% | $5.00 | $16,000 | 0.00% | |||
| 2024-06-03 | director | 3,200 0.0037% | $4.83 | $15,459 | +29.69% | |||
| 2024-05-01 | director | 3,200 0.0035% | $4.68 | $14,982 | +20.84% | |||
| 2024-04-08 | director | 3,200 0.0036% | $6.07 | $19,411 | -6.61% | |||
| 2024-02-20 | Sale | EVP & CHIEF BUSINESS OFFICER | 1,951 0.0026% | $5.48 | $10,691 | +10.21% | ||
| 2024-02-20 | Sale | EVP & CHIEF FINANCIAL OFFICER | 2,593 0.0035% | $5.53 | $14,339 | +10.21% | ||
| 2024-02-20 | Sale | EVP & CHIEF INNOVATION OFFICER | 2,604 0.0035% | $5.51 | $14,348 | +10.21% | ||
| 2024-02-12 | Sale | PRESIDENT AND CEO | 5,782 0.0076% | $5.54 | $32,032 | +4.05% |
Insider Historical Profitability
| Satter Muneer A | 7406024 6.9479% | $5.23 | 3 | 0 | <0.0001% | |
| Love Douglas | PRESIDENT AND CEO | 196121 0.184% | $5.23 | 1 | 9 | +135.71% |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 86468 0.0811% | $5.23 | 1 | 9 | +33.07% |
| Carson William H. | director | 25600 0.024% | $5.23 | 8 | 0 | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 5701926 5.3492% | $5.23 | 2 | 0 | +48.92% |
Institutional Investor Ownership
| Fidelity Investments | $67.2M | 9.06 | 9.37M | -3.23% | -$2.24M | <0.01 | |
| Bain Capital Life Sciences Investors Llc | $62.4M | 8.41 | 8.7M | +7.96% | +$4.6M | 5.02 | |
| Alerce Investment Management L P | $53.1M | 7.16 | 7.41M | 0% | +$0 | 0.62 | |
| Bvf Inc Il | $50.19M | 6.76 | 7M | 0% | +$0 | 0.37 | |
| Redmile Group | $39.46M | 5.32 | 5.5M | 0% | +$0 | 0.4 |